CCNP 46th Annual Meeting
CCNP 46th Annual Meeting
September 25-27, 2024
Calgary, AB

The in-person meeting will be held at the Alt Hotel Calgary University District located at
482 McLaurin St. NW Calgary, AB T3B 6K3

Deadlines: Call for Symposia:
June 14, 2024
  Call for Abstracts:
July 7, 2024

Online registration will be available soon!

We are delighted to showcase our two keynote speakers who are scheduled to present at the CCNP Annual Meeting, 2024:

Dr. Christian G. Schütz

Professor (Partner), UBC Department of Psychiatry, Division of Substance Use & Concurrent Disorders
Head, Division of Substance Use & Concurrent Disorders, UBC Department of Psychiatry
Clinician Scientist, Djavad Mowafaghian Centre for Brain Health
Research, Education and Evaluation Medical Manager, Red Fish Healing Centre for Mental Health and Addiction
Research Lead, Adult Mental Health and Substance Use, BC Mental Health & Substance Use Services, PHSA
Scientist, UBC Centre for Health Evaluation & Outcome Sciences (CHEOS)
Researcher, Vancouver Coastal Health Research Institute
Member, UBC Institute for Mental Health

Dr. Schütz’s main research interests focus on the clinical interventions and health service in substance use disorders and dual diagnoses (mental plus substance use disorders), as well as neurobiological and neurocognitive aspects of impulsive decision making.

His focus is on understanding mechanisms of relapse and impulsive decision-making to improve treatment of addiction and concurrent disorders; developing novel interventions focused on stimulant use disorders; and developing a more comprehensive integrated min/brain-based sound concept of motivation and decision making. Publications include over 160 research articles.

He has made over 250 presentations across Europe and North America, discussing the latest scientific findings about substance use disorders and concurrent disorders.

Dr. Schütz is also involved in BRAIN-Lab.

Dr. Jibran Khokhar

Associate Professor
Ph.D. University of Toronto
B.Sc. Queens University

Dr. Khokhar’s research aims to understand the mechanisms underlying co-occurring serious mental illness and substance use disorders, using a variety of behavioural, pharmacological and translational neuroimaging techniques. In addition, his research interests also include assessing the long-term effects of adolescent drug (e.g., cannabis) use, and how these effects might contribute to the risk for serious mental illness and addiction. Lastly, Dr. Khokhar is also very interested in profiling the pharmacokinetic parameters related to different routes of exposure to drugs like nicotine and cannabis, as well as the impact of development and sex on these profiles. His current projects include: Impact of Vapourized Drugs on Brain Circuit and Function Across Development, Preclinical Neuroimaging for Cp-Occurring Mental Illness and Substance Use in Animal Models and Treatment Development for Psychopathology and Addictive Disorders.

Aims and Objectives of the College

The principal function of the Canadian College of Neuropsychopharmacology (CCNP) is to further research and education in neuropsychopharmacology and related fields. To achieve this function, the CCNP values open communication between membership and leadership related to governance of the CCNP, and encourages its members to support integrity, collegiality, and ethics in research. The CCNP is committed to maintaining a level of excellence in the conduct of science, supporting discovery and scientific dialogue within an environment that encourages the free expression and exchange of scientific and educational ideas. The CCNP has a tradition of providing a forum for exchange of scientific information between clinical and basic scientists, which is critical for the advancement and translation of scientific discovery in neuropsychopharmacology.

Mission

The aim of the College shall be:

a) to provide a forum for clinical and basic science researchers to discuss and exchange ideas and experience in neuropsychopharmacology and to promote the development of this science nationally and internationally.

b) to be a liaison body to educational institutions, public, industry and government organizations as well as other related scientific bodies in order to promote quality of research and treatment in this field.

Journal of Psychiatry & Neuroscience

The official journal of the Canadian College of Neuropsychopharmacology
  • The Journal of Psychiatry & Neuroscience has an impact factor of 6.19 (2020 ISI data) and is ranked at #25 out of 156 Psychiatry journals and #51 out of 273 Neuroscience journals, making it the highest ranking open access journal in biological psychiatry. .
  • Original research and reviews in basic and clinical science.
  • As an open access journal our page charges remain very reasonable with no charge for figures and we are now publishing online only for rapid publication of accepted papers. CCNP members are encouraged to consider JPN for submitting their research (https://jpn.ca).
For more information, visit the website of the Canadian Medical Association.

Revue de psychiatrie & de neuroscience

La revue officielle du Collège canadien de neuropsychopharmacologie
  • Le facteur d'impact de la Revue de psychiatrie et de neuroscience atteint 6,19 (données 2020 de l'ISI), ce qui en fait le journal à accès libre le mieux coté aussi bien dans la catégorie psychiatrie que dans la catégorie neurosciences.
  • Recherche originale et analyses critiques en sciences
      fondamentales et cliniques.
  • Les articles publiés dans ce journal sont accessibles gratuitement au http://jpn.ca/ et via PubMed Central.
Pour obtenir des informations suplémentaires, visitez le site internet de l'Association Médicale Canadienne.